Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
America’s Health Insurance Plans' Monday Accountable Care SmartBrief included an article from The American Journal of Managed Care® (AJMC®). The article, “Analysis Finds Progress in Reducing Progress on Low-Value Services Positive but Sluggish,” covered an analysis of spending on low- and high-value care from 2014 to 2016 and found that despite significant discussion about reducing low-value care, reduction has been slight.
The National Pharmaceutical Council’s Monday CER Daily Newsfeed included an article from AJMC®’s sister site The Center for Biosimilars®. The article, “Real-World Evidence Shows Switching Among ESAs in CKD Is Not Associated With Risks to Safety, Efficacy,” reported that no statistically significant risk in terms of lack of effectiveness or safety was found for patients who switched therapies versus those who remained on their first therapy in either the reference group or the biosimilar group.
Tuesday’s CER Newsfeed included AJMC®’s interview with Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders, in which he discussed factors that have historically been underrepresented in value assessment frameworks for rare disease therapies.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More